Loss/down-regulation of tumor suppressor in lung cancer 1 expression is associated with tumor progression and is a biomarker of poor prognosis in ovarian carcinoma

International Journal of Gynecological Cancer

Volumn 21, Issue 3, 2011, Pages 486-493

  Yang, Guofen ^a,b   He, Weipeng ^a   Cai, Muyan ^b   Luo, Fei ^a   Kung, Hsiangfu ^b   Guan, Xinyuan ^b   Zeng, Yixin ^b   Xie, Dan ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Immunohistochemistry; Ovarian tumor; Prognosis; TSLC1

Indexed keywords

FORMALDEHYDE; PARAFFIN; TUMOR MARKER; CADM1 PROTEIN, HUMAN; CELL ADHESION MOLECULE; IMMUNOGLOBULIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CYSTADENOMA; DISTANT METASTASIS; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR SUPPRESSOR IN LUNG CANCER 1 GENE; UNIVARIATE ANALYSIS; CANCER STAGING; COLLOID CARCINOMA; CYSTADENOCARCINOMA; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CELL ADHESION MOLECULES; CYSTADENOCARCINOMA, SEROUS; DOWN-REGULATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULINS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 80051647936     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31820fa168     Document Type: Article

References (25)

1. Wingo PA, Ries LA, Rosenberg HM, et al. Cancer incidence and mortality. 1973-1995, A report card for the U.S. Cancer. 1998;82:1197-1207. (Pubitemid 28136536)
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66. (Pubitemid 46148091)
3. Lynch HT, Casey MJ, Lynch J, et al. Genetics and ovarian carcinoma. Semin Oncol. 1998;25:265-280. (Pubitemid 28272602)
4. Vaidya AP, Curtin JP. The follow-up of ovarian cancer. Semin Oncol. 2003;30:401-412. (Pubitemid 36706565)
5. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, et al. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol. 2003;189:1120-1127. (Pubitemid 37373908)
6. DiSaia PJ, Bloss JD. Treatment of ovarian cancer: new strategies. Gynecol Oncol. 2003;90:S24-S32.
7. Kuramochi M, Fukuhara H, Nobukuni T, et al. TSLC1 is a tumor suppressor gene in human non-small-cell lung cancer. Nat Genet. 2001;27:427-430. (Pubitemid 32268425)
8. Pletcher MT, Nobukuni T, Fukuhara H, et al. Identification of tumor suppressor candidate genes by physical and sequence mapping of the TSLC1 region of human chromosome 11q23. Gene. 2001;273:181-189. (Pubitemid 32786911)
9. Murakami Y. Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis. Cancer Sci. 2005;96: 543-552. (Pubitemid 41488417)
10. Murakami Y. Functional cloning of a tumor suppressor gene, TSLC1, in human non-small cell lung cancer. Oncogene. 2002;21:6936-6948. (Pubitemid 35221939)
11. Masuda M, Yageta M, Fukuhara H, et al. The tumor suppressor protein TSLC1 is involved in cell-cell adhesion. J Biol Chem. 2002;227:31014-31019. (Pubitemid 34970805)
12. Fukuhara H, Kuramochi M, Nobukuni T, et al. Isolation of the TSLL1 and TSLC2 genes, members of the tumor suppressor TSLC1 gene family encoding transmembrane proteins. Oncogene. 2001;20:5401-5407. (Pubitemid 32844072)
13. Jansen M, Fukushima N, Rosty C, et al. Aberrant methylation of the 5′ CpG island of TSLC1 is common in pancreatic ductaladeno-carcinoma and is first manifest in high-grade PanINs. Cancer Biol Ther. 2002;1:293-296.
14. Allinen M, Peri L, Kujala S, et al. Analysis of 11q21-24 loss of heterozygosity candidate target genes in breast cancer: indications of TSLC1 promoter hypermethylation. Genes Chromosomes Cancer. 2002;34:384-389. (Pubitemid 34787459)
15. Fukuhara H, Kuramochi M, Fukami T, et al. Promoter methylation of TSLC1 and tumor suppression by its gene product in human prostate cancer. Jpn J Cancer Res. 2002;93:605-609. (Pubitemid 34846267)
16. Steenbergen RD, Kramer D, Braakhuis BJ, et al. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst. 2004;96:294-305. (Pubitemid 38256274)
17. Hui AB, Lo KW, Kwong J, et al. Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma. Mol Carcinog. 2003;38:170-178. (Pubitemid 37523709)
18. Honda T, Tamura G, Waki T, et al. Hypermethylation of the TSLC1 gene promoter in primary gastric cancers and gastric cancer cell lines. Jpn J Cancer Res. 2002;93:857-860. (Pubitemid 35012245)
19. Fukami T, Fukuhara H, Kuramochi M, et al. Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines. Int J Cancer. 2003;107:53-59. (Pubitemid 37100085)
20. Goto A, Niki T, Chi-Pin L, et al. Loss of TSLC1 expression in lung adenocarcinoma: relationships with histological subtypes, sex and prognostic significance. Cancer Sci. 2005;96:480-486. (Pubitemid 41387300)
21. Uchino K, Ito A, Wakayama T, et al. Clinical implication and prognostic significance of the tumor suppressor TSLC1 gene detected in adenocarcinoma of the lung. Cancer. 2003;98: 1002-1007. (Pubitemid 37022101)
22. Ito T, Shimada Y, Hashimoto Y, et al. Involvement of TSLC1 in progression of esophageal squamous cell carcinoma. Cancer Res. 2003;63:6320-6326. (Pubitemid 37255179)
23. Xie D, Zeng YX, Wang HJ, et al. Expression of cytoplasmic and nuclear survivin in primary and secondary human glioblastoma. Br J Cancer. 2006;94:108-114. (Pubitemid 43088549)
24. Hirohashi S, Kanai Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci. 2003;94:575-581. (Pubitemid 36975010)
25. Mao X, Seidlitz E, Truant R, et al. Re-expression of TSLC1 in a non-small-cell lung cancer cell line induces apoptosis and inhibits tumor growth. Oncogene. 2004;23:5632-5642. (Pubitemid 39093041)